Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies

Virulence

Volumn 8, Issue 4, 2017, Pages 391-402

  Pouch, Stephanie M ^a   Satlin, Michael J ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

carbapenem resistant Enterobacteriaceae; hematologic malignancy; multi drug resistance; solid organ transplant; stem cell transplant

Indexed keywords

CARBAPENEMASE; COLISTIN; FOSFOMYCIN; GENTAMICIN; IMMUNOSUPPRESSIVE AGENT; KLEBSIELLA PNEUMONIAE CARBAPENEMASE; POLYMYXIN; RIFAMPICIN; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; BACTEREMIA; BLOODSTREAM INFECTION; CANCER PATIENT; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CHILDHOOD CANCER; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); DRUG USE; ENTEROBACTERIACEAE INFECTION; ENZYME ACTIVITY; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL INFECTION; IMMUNOCOMPROMISED PATIENT; KIDNEY TRANSPLANTATION; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LIVER TRANSPLANTATION; MORTALITY RATE; MULTICENTER STUDY (TOPIC); ORGAN TRANSPLANTATION; PATIENT HISTORY OF STEM CELL TRANSPLANTATION; PNEUMONIA; PRACTICE GUIDELINE; REVIEW; STEM CELL TRANSPLANTATION; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; COMPLICATION; DISEASE MANAGEMENT; HEMATOLOGIC DISEASE; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MORTALITY; PREVALENCE;

ANTI-BACTERIAL AGENTS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DISEASE MANAGEMENT; ENTEROBACTERIACEAE INFECTIONS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; PREVALENCE; TRANSPLANT RECIPIENTS;

EID: 84981724895     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.1080/21505594.2016.1213472     Document Type: Review

References (106)

1. Centers for Disease C, Prevention. Vital signs:carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013; 62:165-70; PMID:23466435
2. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011; 17:1791-8; PMID:22000347; https://doi.org/10.3201/eid1710.110655
3. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae:an evolving crisis of global dimensions. Clin Microbiol Rev 2012; 25:682-707; PMID:23034326; https://doi.org/10.1128/CMR.05035-11
4. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29:1099-106; PMID:18973455; https://doi.org/10.1086/592412
5. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52:1028-33; PMID:18086836; https://doi.org/10.1128/AAC.01020-07
6. Falagas ME, Rafailidis PI, Kofteridis D, Virtzili S, Chelvatzoglou FC, Papaioannou V, Maraki S, Samonis G, Michalopoulos A. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections:a matched case control study. J Antimicrob Chemother 2007; 60:1124-30; PMID:17884829; https://doi.org/10.1093/jac/dkm356
7. Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, Kubin CJ. Carbapenem-resistant Klebsiella pneumoniae bacteremia:factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 2010; 67:180-4; PMID:20356699; https://doi.org/10.1016/j.diagmicrobio.2010.02.001
8. Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis 2014; 58:1274-83; PMID:24463280; https://doi.org/10.1093/cid/ciu052
9. Kwon JA, Lee JE, Huh W, Peck KR, Kim YG, Kim DJ, Oh HY. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010; 35:473-7; PMID:20089383; https://doi.org/10.1016/j.ijantimicag.2009.12.002
10. Taber SS, Pasko DA. The epidemiology of drug-induced disorders:the kidney. Expert Opin Drug Saf 2008; 7:679-90; PMID:18983215; https://doi.org/10.1517/14740330802410462
11. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America:results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008–2010). Diagn Microbiol Infect Dis 2012; 73:354-60; PMID:22656912; https://doi.org/10.1016/j.diagmicrobio.2012.04.007
12. Endimiani A, Hujer AM, Perez F, Bethel CR, Hujer KM, Kroeger J, Oethinger M, Paterson DL, Adams MD, Jacobs MR, et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother 2009; 63:427-37; PMID:19155227; https://doi.org/10.1093/jac/dkn547
13. Glasner C, Albiger B, Buist G, Tambic Andrasevic A, Canton R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, et al. Carbapenemase-producing Enterobacteriaceae in Europe:a survey among national experts from 39 countries, February 2013. Euro Surveill 2013; 18. pii:20525; PMID:23870096; https://doi.org/10.2807/1560-7917.ES2013.18.28.20525
14. Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species:emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008; 52:1413-8; PMID:18227191; https://doi.org/10.1128/AAC.01103-07
15. Landman D, Urban C, Backer M, Kelly P, Shah N, Babu E, Bratu S, Quale J. Susceptibility profiles, molecular epidemiology, and detection of KPC-producing Escherichia coli isolates from the New York City vicinity. J Clin Microbiol 2010; 48:4604-7; PMID:20926706; https://doi.org/10.1128/JCM.01143-10
16. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases:the phantom menace. J Antimicrob Chemother 2012; 67:1597-606; PMID:22499996; https://doi.org/10.1093/jac/dks121
17. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK:a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10:597-602; PMID:20705517; https://doi.org/10.1016/S1473-3099(10)70143-2
18. Singh N, Wagener MM, Obman A, Cacciarelli TV, de Vera ME, Gayowski T. Bacteremias in liver transplant recipients:shift toward gram-negative bacteria as predominant pathogens. Liver Transpl 2004; 10:844-9; PMID:15237367; https://doi.org/10.1002/lt.20214
19. Lanini S, Costa AN, Puro V, Procaccio F, Grossi PA, Vespasiano F, Ricci A, Vesconi S, Ison MG, Carmeli Y, et al. Incidence of carbapenem-resistant gram negatives in Italian transplant recipients:a nationwide surveillance study. PLoS One 2015; 10:e0123706; PMID:25835018; https://doi.org/10.1371/journal.pone.0123706
20. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, Cipullo R, Moreira JC, Baia C, Barbosa V, Abboud CS. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis 2012; 14:198-205; PMID:22093103; https://doi.org/10.1111/j.1399-3062.2011.00688.x
21. Clancy CJ, Chen L, Shields RK, Zhao Y, Cheng S, Chavda KD, Hao B, Hong JH, Doi Y, Kwak EJ, et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 2013; 13:2619-33; PMID:24011185; https://doi.org/10.1111/ajt.12424
22. Raviv Y, Shitrit D, Amital A, Fox B, Bakal I, Tauber R, Bishara J, Kramer MR. Multidrug-resistant Klebsiella pneumoniae acquisition in lung transplant recipients. Clin Transplant 2012; 26:E388-94; PMID:22882693; https://doi.org/10.1111/j.1399-0012.2012.01671.x
23. Kalpoe JS, Sonnenberg E, Factor SH, del Rio Martin J, Schiano T, Patel G, Huprikar S. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl 2012; 18:468-74; PMID:22467548; https://doi.org/10.1002/lt.23374
24. Pereira MR, Scully BF, Pouch SM, Uhlemann AC, Goudie S, Emond JE, Verna EC. Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl 2015; 21:1511-19; PMID:26136397; https://doi.org/10.1002/lt.24207
25. Freire MP, Abdala E, Moura ML, de Paula FJ, Spadao F, Caiaffa-Filho HH, David-Neto E, Nahas WC, Pierrotti LC. Risk factors and outcome of infections with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in kidney transplant recipients. Infection 2015; 43:315-23; PMID:25690848; https://doi.org/10.1007/s15010-015-0743-4
26. Cicora F, Mos F, Paz M, Allende NG, Roberti J. Infections with blaKPC-2-producing Klebsiella pneumoniae in renal transplant patients:a retrospective study. Transplantation Proc 2013; 45:3389-93; https://doi.org/10.1016/j.transproceed.2013.07.064
27. Pouch SM, Kubin CJ, Satlin MJ, Tsapepas DS, Lee JR, Dube G, Pereira MR. Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients. Transpl Infect Dis 2015; 17:800-9; PMID:26341757; https://doi.org/10.1111/tid.12450
28. Simkins J, Muggia V, Cohen HW, Minamoto GY. Carbapenem-resistant Klebsiella pneumoniae infections in kidney transplant recipients:a case-control study. Transpl Infect Dis 2014; 16:775-82; PMID:25092500; https://doi.org/10.1111/tid.12276
29. Varghese J, Jayanthi V, Rela M. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl 2012; 18:1124; author reply 5; PMID:22927143; https://doi.org/10.1002/lt.23464
30. Taglietti F, Di Bella S, Galati V, Topino S, Iappelli M, Petrosillo N. Carbapenemase-producing Klebsiella pneumoniae-related mortality among solid organ-transplanted patients:do we know enough? Transpl Infect Dis 2013; 15:E164-5; PMID:23601113; https://doi.org/10.1111/tid.12085
31. Mouloudi E, Massa E, Papadopoulos S, Iosifidis E, Roilides I, Theodoridou T, Piperidou M, Orphanou A, Passakiotou M, Imvrios G, et al. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae among intensive care unit patients after orthotopic liver transplantation:risk factors for infection and impact of resistance on outcomes. Transplant Proc 2014; 46:3216-8; PMID:25420863; https://doi.org/10.1016/j.transproceed.2014.09.159
32. Mathers AJ, Cox HL, Bonatti H, Kitchel B, Brassinga AK, Wispelwey B, Sawyer RG, Pruett TL, Hazen KC, Patel JB, et al. Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients. Transpl Infect Dis 2009; 11:257-65; PMID:19254325; https://doi.org/10.1111/j.1399-3062.2009.00374.x
33. Brizendine KD, Richter SS, Cober ED, van Duin D. Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation. Antimicrob Agents Chemother 2015; 59:553-7; PMID:25385105; https://doi.org/10.1128/AAC.04284-14
34. Huprikar S, Casner L, Pierrotti LC, Nellore A, Madan R, Garcia-Diaz J, Jacobs S, Lee D, Trindade Clemente W, Alangaden G, et al. Outcomes associated with carbapenem-resistant Enterobacteriaceae infection after solid organ transplantation in a multicenter study. In:Program and abstracts of the 16th American Transplant Congress, American Society of Transplant Surgeons and the American Society of Transplantation, Boston, MA, 2016.
35. Chen H, Zhang Y, Chen YG, Yu YS, Zheng SS, Li LJ. Sepsis resulting from Enterobacter aerogenes resistant to carbapenems after liver transplantation. Hepatobiliary Pancreat Dis Int 2009; 8:320-2; PMID:19502176
36. Bennett JW, Herrera ML, Lewis JS, 2nd, Wickes BW, Jorgensen JH. KPC-2-producing Enterobacter cloacae and Pseudomonas putida coinfection in a liver transplant recipient. Antimicrob Agents Chemother 2009; 53:292-4; PMID:18852270; https://doi.org/10.1128/AAC.00931-08
37. Lai CC, Lin TL, Tseng SP, Huang YT, Wang JT, Chang SC, Teng LJ, Wang JT, Hsueh PR. Pelvic abscess caused by New Delhi metallo-β-lactamase-1-producing Klebsiella oxytoca in Taiwan in a patient who underwent renal transplantation in China. Diagn Microbiol Infect Dis 2011; 71:474-5; PMID:22083082; https://doi.org/10.1016/j.diagmicrobio.2011.09.004
38. Giani T, Conte V, Mandala S, D'Andrea MM, Luzzaro F, Conaldi PG, Grossi P, Rossolini GM. Cross-infection of solid organ transplant recipients by a multidrug-resistant Klebsiella pneumoniae isolate producing the OXA-48 carbapenemase, likely derived from a multiorgan donor. J Clin Microbiol 2014; 52:2702-5; PMID:24759725; https://doi.org/10.1128/JCM.00511-14
39. Mouloudi E, Massa E, Piperidou M, Papadopoulos S, Iosifidis E, Roilides I, Theodoridou T, Kydona C, Fouzas I, Imvrios G, et al. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit:a 3-year study. Transplant Proc 2014; 46:3219-21; PMID:25420864; https://doi.org/10.1016/j.transproceed.2014.09.160
40. Rana MM, Sturdevant M, Patel G, Huprikar S. Klebsiella necrotizing soft tissue infections in liver transplant recipients:a case series. Transpl Infect Dis 2013; 15:E157-63; PMID:23782431; https://doi.org/10.1111/tid.12103
41. Lubbert C, Becker-Rux D, Rodloff AC, Laudi S, Busch T, Bartels M, Kaisers UX. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality:a case-control analysis. Infection 2014; 42:309-16; PMID:24217959; https://doi.org/10.1007/s15010-013-0547-3
42. Lubbert C, Rodloff AC, Laudi S, Simon P, Busch T, Mossner J, Bartels M, Kaisers UX. Lessons learned from excess mortality associated with Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in liver transplant recipients. Liver Transpl 2014; 20:736-8; PMID:24677425; https://doi.org/10.1002/lt.23858
43. Ariza-Heredia EJ, Patel R, Blumberg EA, Walker RC, Lewis R, Evans J, Sankar A, Willliams MD, Rogers J, Milano C, et al. Outcomes of transplantation using organs from a donor infected with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae. Transpl Infect Dis 2012; 14:229-36; PMID:22624726; https://doi.org/10.1111/j.1399-3062.2012.00742.x
44. Goldberg E, Bishara J, Lev S, Singer P, Cohen J. Organ transplantation from a donor colonized with a multidrug-resistant organism:a case report. Transpl Infect Dis 2012; 14:296-9; PMID:22176504; https://doi.org/10.1111/j.1399-3062.2011.00697.x
45. Mularoni A, Bertani A, Vizzini G, Gona F, Campanella M, Spada M, Gruttadauria S, Vitulo P, Conaldi P, Luca A, et al. Outcome of transplantation using organs from donors infected or colonized with carbapenem-resistant gram-negative bacteria. Am J Transplant 2015; 15:2674-82; PMID:25981339; https://doi.org/10.1111/ajt.13317
46. van Duin D, van Delden C, AST ID COP. Multidrug-resistant gram-negative bacteria infections in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:31-41; PMID:23464996; https://doi.org/10.1111/ajt.12096
47. Bishara J, Goldberg E, Lev S, Singer P, Ashkenazi T, Cohen J. The utilization of solid organs for transplantation in the setting of infection with multidrug-resistant organisms:an expert opinion. Clin Transplant 2012; 26:811-5; PMID:22831178; https://doi.org/10.1111/j.1399-0012.2012.01693.x
48. Huprikar S, Casner L, Pouch S, Pierrotti LC, Madan R, Kwak EJ, Satlin M, Hartman P, Pisney L, Trindade Clemente W, La Hoz R, et al. Pre-transplant carbapenem-resistant Enterobacteriaceae is not an absolute contraindication for solid organ transplantation. In:Program and abstracts of the 16th American Transplant Congress, American Society of Transplant Surgeons and the American Society of Transplantation, Boston, MA 2016.
49. Trecarichi EM, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R, Nosari A, Caira M, Spadea A, Busca A, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies:an Italian multicentre prospective survey. Clin Microbiol Infect 2015; 21:337-43; PMID:25595706; https://doi.org/10.1016/j.cmi.2014.11.022
50. Gudiol C, Bodro M, Simonetti A, Tubau F, Gonzalez-Barca E, Cisnal M, Domingo-Domenech E, Jiménez L, Carratalà J. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 2013; 19:474-9; PMID:22524597; https://doi.org/10.1111/j.1469-0691.2012.03879.x
51. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007; 30 Suppl 1:S51-9; PMID:17689933; https://doi.org/10.1016/j.ijantimicag.2007.06.012
52. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer:2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56-93; PMID:21258094; https://doi.org/10.1093/cid/cir073
53. Hussein K, Raz-Pasteur A, Finkelstein R, Neuberger A, Shachor-Meyouhas Y, Oren I, Kassis I. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect 2013; 83:307-13; PMID:23313086; https://doi.org/10.1016/j.jhin.2012.10.012
54. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, et al. Infections caused by KPC-producing Klebsiella pneumoniae:differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015; 70:2133-43; PMID:25900159; https://doi.org/10.1093/jac/dkv200
55. Satlin MJ CL, Patel G, et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in New York and New Jersey:a clinical and molecular epidemiologic analysis [Abstract 209]. In:Program and abstracts of IDWeek 2015, Infectious Diseases Society of America, San Diego, CA 2015.
56. Satlin MJ CM, Ma K, et al. Prevalence, risk factors, and outcomes of bacteremia caused by carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies [Abstract 434]. In:Program and abstracts of IDWeek 2014, Infectious Diseases Society of America, Philadelphia, PA, 2014.57.
57. Trecarichi EM TM, DiBlasi R, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients:incidence and clinical impact of carbapenem resistance in a multicenter prospective survey [Abstract 3757]. In:Program and abstracts of the 57th American Society for Hematology Meeting & Exposition, American Society for Hematology, Orlando, FL, 2015.
58. Pagano L, Caira M, Trecarichi EM, Spanu T, Di Blasi R, Sica S, Sanguinetti M, Tumbarello M. Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. Emerg Infect Dis 2014; 20:1235-6; PMID:24960464; https://doi.org/10.3201/eid2007.130094
59. Andria N, Henig O, Kotler O, Domchenko A, Oren I, Zuckerman T, Ofran Y, Fraser D, Paul M. Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients:a retrospective cohort study. J Antimicrob Chemother 2015; 70:3146-53; PMID:26209312; https://doi.org/10.1093/jac/dkv218
60. Caselli D, Cesaro S, Fagioli F, Carraro F, Ziino O, Zanazzo G, Meazza C, Colombini A, Castagnola E, Infectious Diseases Study Group of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Incidence of colonization and bloodstream infection with carbapenem-resistant Enterobacteriaceae in children receiving antineoplastic chemotherapy in Italy. Infect Dis 2016; 48:152-5; https://doi.org/10.3109/23744235.2015.1087647
61. Balkan II, Aygun G, Aydin S, Mutcali SI, Kara Z, Kuskucu M, Midilli K, Şemen V, Aras S, Yemişen M, et al. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae:treatment and survival. Int J Infect Dis 2014; 26:51-6; PMID:24998423; https://doi.org/10.1016/j.ijid.2014.05.012
62. Zhang LP, Xue WC, Meng DY. First report of New Delhi metallo-β-lactamase 5 (NDM-5)-producing Escherichia coli from blood cultures of three leukemia patients. Int J Infect Dis 2016; 42:45-6; PMID:26482388; https://doi.org/10.1016/j.ijid.2015.10.006
63. Goel G, Hmar L, Sarkar De M, Bhattacharya S, Chandy M. Colistin-resistant Klebsiella pneumoniae:report of a cluster of 24 cases from a new oncology center in eastern India. Infect Control Hosp Epidemiol 2014; 35:1076-7; PMID:25026633; https://doi.org/10.1086/677170
64. Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D, Sica S, Severino A, Cudillo L, Ciceri F, et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients:a nationwide retrospective survey from Italy. Bone Marrow Transplant 2015; 50:282-8; PMID:25310302; https://doi.org/10.1038/bmt.2014.231
65. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006:overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091-100; PMID:20218877; https://doi.org/10.1086/651263
66. Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. Open Forum Infect Dis 2015; 2:ofv050; PMID:26125030; https://doi.org/10.1093/ofid/ofv050
67. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens:results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66:2070-4; PMID:21715434; https://doi.org/10.1093/jac/dkr239
68. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53:879-84; PMID:21900484; https://doi.org/10.1093/cid/cir611
69. Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 2012; 65:80-7; PMID:22326553; https://doi.org/10.1016/j.jinf.2012.01.015
70. Bergen PJ, Landersdorfer CB, Zhang J, Zhao M, Lee HJ, Nation RL, Li J. Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins:what is new? Diagn Microbiol Infect Dis 2012; 74:213-23; PMID:22959816; https://doi.org/10.1016/j.diagmicrobio.2012.07.010
71. Rao GG, Ly NS, Haas CE, Garonzik S, Forrest A, Bulitta JB, Kelchlin PA, Holden PN, Nation RL, Li J, et al. New dosing strategies for an old antibiotic:pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease. Antimicrob Agents Chemother 2014; 58:1381-8; PMID:24342636; https://doi.org/10.1128/AAC.00327-13
72. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, Samonis G. Aerosolized plus intravenous colistin vs. intravenous colistin alone for the treatment of ventilator-associated pneumonia:a matched case-control study. Clin Infect Dis 2010; 51:1238-44; PMID:20973727; https://doi.org/10.1086/657242
73. Tumbarello M, De Pascale G, Trecarichi EM, De Martino S, Bello G, Maviglia R, Spanu T, Antonelli M. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 2013; 144:1768-75; PMID:23989805; https://doi.org/10.1378/chest.13-1018
74. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae:importance of combination therapy. Clin Infect Dis 2012; 55:943-50; PMID:22752516; https://doi.org/10.1093/cid/cis588
75. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections:lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58:2322-8; PMID:24514083; https://doi.org/10.1128/AAC.02166-13
76. Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, Jenkins SG, Calfee DP. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011; 55:5893-9; PMID:21968368; https://doi.org/10.1128/AAC.00387-11
77. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621-9; PMID:3927867; https://doi.org/10.1001/archinte.1985.00360090089015
78. van Duin D, Cober E, Richter SS, Perez F, Kalayjian RC, Salata RA, Evans S, Fowler VG, Jr, Kaye KS, Bonomo RA. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2015; 70:1203-11; PMID:25492391
79. Endimiani A, Patel G, Hujer KM, Swaminathan M, Perez F, Rice LB, Jacobs MR, Bonomo RA. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 2010; 54:526-9; PMID:19901089; https://doi.org/10.1128/AAC.01235-09
80. Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother 2012; 56:5744-8; PMID:22926565; https://doi.org/10.1128/AAC.00402-12
81. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007; 29:62-5; PMID:17189097; https://doi.org/10.1016/j.ijantimicag.2006.08.039
82. Jernigan MG, Press EG, Nguyen MH, Clancy CJ, Shields RK. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2012; 56:3395-8; PMID:22430958; https://doi.org/10.1128/AAC.06364-11
83. Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, Landman D. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY:molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005; 56:128-32; PMID:15917285; https://doi.org/10.1093/jac/dki175
84. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae:superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56:2108-13; PMID:22252816; https://doi.org/10.1128/AAC.06268-11
85. Cardile AP, Briggs H, Burguete SR, Herrera M, Wickes BL, Jorgensen JH. Treatment of KPC-2 Enterobacter cloacae empyema with cefepime and levofloxacin. Diagn Microbiol Infect Dis 2014; 78:199-200; PMID:24268534; https://doi.org/10.1016/j.diagmicrobio.2013.10.012
86. de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. In Vitro Susceptibility of Carbapenem Non-Susceptible Enterobacteriaceae to Ceftazidime-Avibactam:INFORM Global Surveillance 2012-2014. Antimicrob Agents Chemother 2016; 60(5):3163-9.
87. Mlynarczyk G, Kosykowska E, de Walthoffen SW, Szymanek-Majchrzak K, Sawicka-Grzelak A, Baczkowska T, et al. A threat of the Klebsiella pneumoniae carbapenemase-producing strains among transplant recipients. Transplant Proc 2011; 43:3135-6; PMID:21996247; https://doi.org/10.1016/j.transproceed.2011.08.004
88. Kassis-Chikhani N, Saliba F, Carbonne A, Neuville S, Decre D, Sengelin C, Guerin C, Gastiaburu N, Lavigne-Kriaa A, Boutelier C, et al. Extended measures for controlling an outbreak of VIM-1 producing imipenem-resistant Klebsiella pneumoniae in a liver transplant centre in France, 2003-2004. Euro Surveill 2010; 15. pii:19713; PMID:AMBIGUOUS.
89. Centers for Disease Control and Prevention (CDC). Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE). November 2015 Update - CRE Toolkit. Available at http://www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf (Accessed February28, 2016).
90. Epstein L, Hunter JC, Arwady MA, Tsai V, Stein L, Gribogiannis M, Frias M, Guh AY, Laufer AS, Black S, et al. New Delhi metallo-β-lactamase-producing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopes. JAMA 2014; 312:1447-55; PMID:25291580; https://doi.org/10.1001/jama.2014.12720
91. Wendorf KA, Kay M, Baliga C, Weissman SJ, Gluck M, Verma P, D'Angeli M, Swoveland J, Kang MG, Eckmann K, et al. Endoscopic retrograde cholangiopancreatography-associated AmpC Escherichia coli outbreak. Infect Control Hosp Epidemiol 2015; 36:634-42; PMID:25817743; https://doi.org/10.1017/ice.2015.66
92. Centers for Disease Control and Prevention (CDC). Interim Duodenoscope Surveillance Protocol. Available at http://www.cdc.gov/hai/organisms/cre/cre-duodenoscope-surveillance-protocol.html#ref1 (Accessed February28, 2016).
93. Centers for Disease Control and Prevention. Notes from the Field:New Delhi metallo-β-lactamase-producing Escherichia coli associated with endoscopic retrograde cholangiopancreatography - Illinois, 2013. MMWR Morb Mortal Wkly Rep 2014; 62:1051; PMID:24381080
94. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates:risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009; 30:666-71; PMID:19496647; https://doi.org/10.1086/598244
95. Giannella M, Bartoletti M, Morelli MC, Tedeschi S, Cristini F, Tumietto F, Pasqualini E, Danese I, Campoli C, Lauria ND, et al. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation:the importance of pre- and posttransplant colonization. Am J Transplant 2015; 15:1708-15; PMID:25754742; https://doi.org/10.1111/ajt.13136
96. Saidel-Odes L, Polachek H, Peled N, Riesenberg K, Schlaeffer F, Trabelsi Y, Eskira S, Yousef B, Smolykov R, Codish S, et al. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol 2012; 33:14-9; PMID:22173517; https://doi.org/10.1086/663206
97. Tascini C, Sbrana F, Flammini S, Tagliaferri E, Arena F, Leonildi A, Ciullo I, Amadori F, Di Paolo A, Ripoli A, et al. Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections:relevance of concomitant systemic antibiotic therapy. Antimicrob Agents Chemother 2014; 58:1972-6; PMID:24419337; https://doi.org/10.1128/AAC.02283-13
98. Zuckerman T, Benyamini N, Sprecher H, Fineman R, Finkelstein R, Rowe JM, Oren I. SCT in patients with carbapenem resistant Klebsiella pneumoniae:a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant 2011; 46:1226-30; PMID:21057549; https://doi.org/10.1038/bmt.2010.279
99. Lubbert C, Faucheux S, Becker-Rux D, Laudi S, Durrbeck A, Busch T, Gastmeier P, Eckmanns T, Rodloff AC, Kaisers UX. Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae:a single-centre experience. Int J Antimicrob Agents 2013; 42:565-70; PMID:24100228; https://doi.org/10.1016/j.ijantimicag.2013.08.008
100. Abboud CS, Bergamasco MD, Sousa EE, Zandonadi Ede C, Cortez D. Successful use of gentamycin as an antibiotic prophylaxis regimen to reduce the rate of healthcare-associated infections after renal transplantation. Braz J Infect Dis 2013; 17:254-5; PMID:23453411; https://doi.org/10.1016/j.bjid.2012.10.016
101. Blaschke AJ, Heyrend C, Byington CL, Fisher MA, Barker E, Garrone NF, Thatcher SA, Pavia AT, Barney T, Alger GD, et al. Rapid identification of pathogens from positive blood cultures by multiplex polymerase chain reaction using the FilmArray system. Diagn Microbiol Infect Dis 2012; 74:349-55; PMID:22999332; https://doi.org/10.1016/j.diagmicrobio.2012.08.013
102. Hrabak J, Studentova V, Walkova R, Zemlickova H, Jakubu V, Chudackova E, Gniadkowski M, Pfeifer Y, Perry JD, Wilkinson K, et al. Detection of NDM-1, VIM-1, KPC, OXA-48, and OXA-162 carbapenemases by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2012; 50:2441-3; PMID:22553235; https://doi.org/10.1128/JCM.01002-12
103. Hill JT, Tran KD, Barton KL, Labreche MJ, Sharp SE. Evaluation of the nanosphere Verigene BC-GN assay for direct identification of gram-negative bacilli and antibiotic resistance markers from positive blood cultures and potential impact for more-rapid antibiotic interventions. J Clin Microbiol 2014; 52:3805-7; PMID:25122857; https://doi.org/10.1128/JCM.01537-14
104. Freire MP, Pierrotti LC, Filho HHC, Ibrahim KY, Magri ASGK, Bonazzi PR, Hajar L, Diz MPE, Pereira J, Hoff PM, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients. Eur J Clin Microbiol Infect Dis 2015; 34:277-86; PMID:25169967; https://doi.org/10.1007/s10096-014-2233-5
105. Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, Shrestha NK, Fraser TG, van Duin D. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis 2011; 69:357-62; PMID:21396529; https://doi.org/10.1016/j.diagmicrobio.2010.10.013
106. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, NISC Comparative Sequencing Program Group, Henderson DK, Palmore TN, Segre JA. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 2012; 4:148ra116; PMID:22914622; https://doi.org/10.1126/scitranslmed.3004129